Treatment of hypothyroidism

Author(s):  
Anthony Toft

Treatment of primary hypothyroidism is usually both gratifying and simple and, in most cases, lifelong. Thyroxine, as l-thyroxine sodium, is the therapy of choice and is available in the UK as tablets of 25, 50, and 100 μ‎g. A greater variety of tablet strength is marketed in other parts of Europe and North America. Thyroxine has a half-life of some 7 days and should be given as a single daily dose which improves compliance. Thyroxine, taken at bedtime, is associated with higher thyroid hormone concentrations and lower thyroid-stimulating hormone (TSH) concentrations compared to the same dose taken in the morning, probably due to greater gastrointestinal uptake of thyroxine during the night (1). Omitting the occasional tablet is of no consequence and those who forget to take their medication, e.g. on vacation, will experience little in the way of symptoms for the first 2 weeks.

PEDIATRICS ◽  
1983 ◽  
Vol 72 (6) ◽  
pp. 817-818
Author(s):  
PETER S. HESSLEIN

In this issue of Pediatrics, Shahar and associates have added yet another testimonial on the efficacy of amiodarone in the treatment of the tachydysrhythmias associated with the Wolff-Parkinson-White syndrome.1 Besides the drug's excellent therapeutic success rate,2-5 it appears to have other advantages over standard antidysrhythmic agents. Because its half-life is measured in days or weeks, a single daily dose is sufficient, and occasional missed doses are inconsequential. Unlike most standard agents, amiodarone does not significantly depress ventricular function,6 which may be an important consideration in patients with congestive heart failure or reduced ventricular function. Last, and most appealing, is the seeming safety of this agent.


1977 ◽  
Vol 131 (2) ◽  
pp. 168-171 ◽  
Author(s):  
Vincent E. Ziegler ◽  
David A. Meyer ◽  
Samuel H. Rosen ◽  
John W. Knesevich ◽  
John T. Biggs

SummaryPlasma levels of amitriptyline and nortriptyline were similar in ten depressed patients after administration of amitriptyline hydrochloride in three divided doses or as a single daily dose. Maximum comparability of the plasma levels is achieved by sampling 12 to 16 hours after the single daily dose, or 3 to 7 hours after the morning dose on a thrice-daily schedule. Owing to the long biological half-life of these drugs, therapeutic plasma levels are maintained on a once a day dosage schedule, and the need for sustained release preparations appears questionable.


Author(s):  
Ruth D. Nass

Congenital hypothyroidism (CH) affects approximately 1 in 3,500 newborns. There is a female preponderance. In areas of iodine insufficiency, the incidence is higher, since iodine is a key element in the synthesis of thyroid hormone. Approximately 85% of CH cases are sporadic, whereas 15% are hereditary. Thyroid hormone is essential for normal pre- and postnatal brain development. The importance of in utero thyroid hormone status is demonstrated by the fact that maternal hypothyroidism during pregnancy is known to result in cognitive and motor deficits in the offspring (Forrest 2004; Zoeller and Rovet 2004). Congenital hypothyroidism is already expressed in fetal life; maternal T4, transferred via the placenta, is not sufficient for normal brain development (Forrest 2004; Haddow et al. 1999; Opazo et al. 2008; Pop and Vulsma 2005). Prior to newborn screening, CH that went undiagnosed and untreated for more than 3 months was associated with permanent and significant mental retardation, as well as behavioral problems. Outcome is now significantly better. Children with CH have normal intelligence, although subtle and specific cognitive and behavioral problems occur. Congenital hypothyroidism can be caused by primary hypothyroidism, due to a defect of the thyroid gland, or by central hypothyroidism secondary to defective hypothalamic or pituitary regulation of thyroid hormone. Several types of primary thyroid abnormalities may occur. Thyroid dysgenesis is the result of a missing, ectopic, or hypoplastic gland. Proteins that are crucial for normal thyroid gland development include the thyroid transcription factors PAX8, TTF1, TTF2, FOXE1 and the thyroid stimulating hormone (TSH) receptor gene. Thyroid dyshormonogenesis is generally due to an autosomal recessive genetic defect in any of many stages of thyroid hormone synthesis, secretion and transport (Moreno and Visser 2007). One in 50,000 children has autosomal dominant thyroid hormone resistance (RTH) due to a mutation in the gene encoding for the TRb thyroid receptors (Hauser et al. 1993; Weiss et al. 1993). Iodine deficiency can also cause CH (endemic cretinism) (DeLange et al. 2000). Gaudino and colleagues (2005) determined the etiology of CH in 49 non-athyroid cases.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Mitsuru Ichii ◽  
Katsuhito Mori ◽  
Daichi Miyaoka ◽  
Mika Sonoda ◽  
Yoshihiro Tsujimoto ◽  
...  

Abstract Background Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone homeostasis. Case presentation We present here a patient undergoing hemodialysis with primary hypothyroidism receiving levothyroxine replacement, who showed decreased free thyroxine (FT4) and thyroid stimulating hormone (TSH) after starting roxadustat. Pituitary stimulation test revealed selective suppression of TSH secretion. Recovery of TSH and FT4 levels after stopping roxadustat suggested the suppression of TSH was reversible. Conclusions Physicians should pay special attention to thyroid hormone abnormalities in treatment with roxadustat.


Author(s):  
Marius N. Stan

Current assays measure thyrotropin (previously called thyroid-stimulating hormone) concentrations as low as 0.01 mIU/L, allowing differentiation between low-normal values and suppressed values. In patients with normal pituitary, thyrotropin levels are increased in primary hypothyroidism, during recovery from nonthyroid illness, and with thyroid hormone resistance. Thyrotropin levels are low in hyperthyroidism, in nonthyroidal illness, in the first trimester of pregnancy, and with the use of certain drugs (eg, somatostatin, dopamine, and glucocorticoids). Measurement of the thyrotropin level is the best single test of thyroid function in these patients.


1970 ◽  
Vol 8 (19) ◽  
pp. 73-75

IODINE METABOLISM AND THE THYROID - The thyroid gland concentrates iodide which is oxidised in the gland and later released as iodinated amino acids thyroxine (tetra-iodothyronine) (T4) and liothyronine (tri-iodothyronine) (T3) - mainly T4. T4 and T3 are transported in the blood almost completely bound to thyroxine binding globulin (TBG). Thyroid hormone release is regulated by thyroid stimulating hormone (TSH) from the pituitary, which is in turn controlled by thyrotrophin releasing factor from the hypothalamus. This mechanism responds to plasma levels of thyroid hormone. In hypothyroidism due to disease of the thyroid itself (primary hypothyroidism), blood levels of TSH are high; in hypothyroidism due to pituitary disease (secondary hypothyroidism) they are low. Iodide is largely excreted passively through the kidney. Extra-thyroidal sites of iodide concentration are not influenced by TSH, but may be relevant to the diagnostic and therapeutic use of radio-iodine, e.g. during lactation.


1994 ◽  
Vol 131 (4) ◽  
pp. 331-340 ◽  
Author(s):  
Paolo Beck-Peccoz ◽  
Luca Persani

Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 1994;131:331–40. ISSN 0804–4643 Thyroid-stimulating hormone (TSH), like the other pituitary glycoprotein hormones, is produced and secreted as a mixture of isoforms, the majority of which represent differences in oligosaccharide structure and possess different bioactivity. When samples are quantified simultaneously by immunometric assay and bioassay, the ratio between bioactivity (B) and immunoreactivity (I) may serve as an index of the overall potency of TSH. Variations of the TSH B/I ratio have been documented in both physiological and pathological conditions associated with alteration of the two most important mechanisms controlling TSH synthesis and secretion, i.e. TRH release and the thyroid hormone feedback system. Major examples of this assumption are the low TSH bioactivity found in samples from patients lacking TRH and thus bearing a hypothalamic hypothyroidism, and the enhanced bioactivity that is invariably found in TSH from patients with thyroid hormone resistance. Moreover, variations of TSH bioactivity have been recorded in normal subjects during the nocturnal TSH surge, in normal fetuses during the last trimester of pregnancy, in patients with primary hypothyroidism and in patients with TSH-secreting pituitary adenoma and non-thyroidal illness. In conclusion, the secretion of TSH molecules with altered bioactivity plays an important pathogenetic role in various thyroid disorders, while in some particular physiological conditions the bioactivity of TSH may vary in order to adjust thyroid hormone secretion to temporary needs. Paolo Beck-Peccoz, Istituto di Scienze Endocrine, Ospedale Maggiore IRCCS, Via F. Sforza 35, 1-20122 Milano, Italy


Sign in / Sign up

Export Citation Format

Share Document